Physician profile
Edith Nottage
NPI 1083755128
$1,162.16
in general payments reported to CMS, 2019-2025
9 companies · $393 in 2025
The $393 reported for 2025 was more than what 96% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $151 · 2024: $618 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $293.72 | 2023-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $234.88 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $197.56 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.09 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Intercept Pharmaceuticals, INC. | $124.57 | 2023-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $62.22 | 2023-2024 | Dificid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.04 | 2025 | Caplyta |
| Braintree Laboratories, INC. | $22.59 | 2024 | Sutab, Suflave |
| Orphalan INC | $18.49 | 2025 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Nottage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.